These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 18379503)

  • 21. Levetiracetam efficacy in epileptic syndromes with continuous spikes and waves during slow sleep: experience in 12 cases.
    Aeby A; Poznanski N; Verheulpen D; Wetzburger C; Van Bogaert P
    Epilepsia; 2005 Dec; 46(12):1937-42. PubMed ID: 16393159
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment and long-term follow-up of post-anoxic myoclonus].
    Janszky J; Holló A; Halász P
    Orv Hetil; 2001 Sep; 142(38):2091-3. PubMed ID: 11697066
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Vinpotropil in the treatment of dyscirculatory encephalopathy with cognitive impairment without dementia].
    Zakharov VV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(11 Pt 1):13-6. PubMed ID: 21183916
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The effect of cerebrolysin on moderate cognitive impairment in cerebral vascular insufficiency (a clinical and electrophysiological study)].
    Damulin IV; Koberskaia NN; Mkhitarian EA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2007; 107(5):32-8. PubMed ID: 18379494
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Piracetam improves visuomotor and cognitive deficits in early Parkinsonism--a pilot study.
    Oepen G; Eisele K; Thoden U; Birg W
    Pharmacopsychiatry; 1985 Nov; 18(6):343-6. PubMed ID: 4089014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Dynamics of cognitive and emotional-volitional disorders in children and adolescents with refractory epilepsy during the treatment with levetiracetam].
    Popov IuV; Iakovleva IuA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(5 Pt 2):48-52. PubMed ID: 23739514
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Piracetam treatment in patients with cognitive impairment.
    Rao MG; Holla B; Varambally S; Raveendranathan D; Venkatasubramanian G; Gangadhar BN
    Gen Hosp Psychiatry; 2013; 35(4):451.e5-6. PubMed ID: 22763000
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Vasobral in the treatment of brain lesions: views of physicians and patients].
    Kamchatnov PR
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(1):23-5. PubMed ID: 23528488
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effectiveness of parenteral administration of piracetam in acute and chronic consciousness disorders in cerebral arteriosclerosis].
    Sobczyk W
    Neurol Neurochir Pol; 1980; 14(2):177-82. PubMed ID: 6993975
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Tanakan as a multimodal cytoprotective factor in general medicine].
    Naprienko MV; Esin RG; Mukhametova ER; Esin OR; Smekalkina LV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(11):146-151. PubMed ID: 27030838
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Moderate cognitive impairment syndrome in cerebral vascular insufficiency].
    Iakhno NN; Zakharov VV; Lokshina AB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(2):13-7. PubMed ID: 15793903
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Gibel A; Ritsner MS
    Clin Neuropharmacol; 2008; 31(4):204-20. PubMed ID: 18670244
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Noben (idebenone) in the treatment of dementia and memory impairment without dementia].
    Voronkova KV; Meleshkov MN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(4):27-32. PubMed ID: 18454094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The use of vinpocetine in chronic disorders caused by cerebral hypoperfusion].
    Horváth S
    Orv Hetil; 2001 Feb; 142(8):383-9. PubMed ID: 11263076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Efficacy and tolerability of choline alphoscerate (cereton) in patients with Parkinson's disease with cognitive disorders].
    Levin OS; Batukaeva LA; Anikina MA; Iunishchenko NA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(11):42-6. PubMed ID: 20032953
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pathophysiological rationale for the use of piracetam in sudden deafness].
    García Callejo FJ; Velert Vila MM; Morant Ventura A; Orts Alborch MH; Marco Algarra J; Blay Galaud L
    Acta Otorrinolaringol Esp; 2000 May; 51(4):319-26. PubMed ID: 10984955
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Efficacy of dynamic magnetic therapy in the complex treatment of cognitive disturbances in patients with chronic cerebrovascular insufficiency].
    Orekhova EM; Svistunov AA; Konchugova TV; Prikazchikova OA; Raĭgorodskiĭ IuM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(2):59-62. PubMed ID: 19385120
    [No Abstract]   [Full Text] [Related]  

  • 38. Clinical efficacy of piracetam in cognitive impairment: a meta-analysis.
    Waegemans T; Wilsher CR; Danniau A; Ferris SH; Kurz A; Winblad B
    Dement Geriatr Cogn Disord; 2002; 13(4):217-24. PubMed ID: 12006732
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Vinpotropile in the treatment of cerebral vascular diseases].
    Filimonov VA; Kliueva VN; Kondrasheva IN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2007; 107(2):58-60. PubMed ID: 18689000
    [No Abstract]   [Full Text] [Related]  

  • 40. Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia.
    Turner DC; Clark L; Pomarol-Clotet E; McKenna P; Robbins TW; Sahakian BJ
    Neuropsychopharmacology; 2004 Jul; 29(7):1363-73. PubMed ID: 15085092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.